Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Experience with the Atypical Antipsychotics—Risperidone and Olanzapine in the Elderly

Experience with the Atypical Antipsychotics—Risperidone and Olanzapine in the Elderly There is paucity of published data regarding controlled trials with risperidone and olanzapine in elderly psychotic patients. Medical records of 151 hospitalized geropsychiatric patients (risperidone patients n = 114 and olanzapine patients n = 37) were analyzed for demographic data, target symptoms, doses, effects, side effects, comorbid medical conditions and concurrent medications. The mean age of the patients was 71 years. The male: female ratio was essentially the same for both groups. The mean daily dose was 3 mg for risperidone and 10 mg for olanzapine. 78% of the risperidone group and 75% of the olanzapine group appear to have responded to treatment. The discontinuation rates of medication was the same in both groups (22%). Adverse events were reported in 16–17% in both groups. It appears from this study that both risperidone and olanzapine are relatively safe and effective in geropsychiatric patients with comorbid medical illnesses. Controlled studies and head-to-head comparison studies are recommended. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Experience with the Atypical Antipsychotics—Risperidone and Olanzapine in the Elderly

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/experience-with-the-atypical-antipsychotics-risperidone-and-olanzapine-0c0S2QuyCT
Publisher
Springer Journals
Copyright
Copyright © 1999 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022351725541
Publisher site
See Article on Publisher Site

Abstract

There is paucity of published data regarding controlled trials with risperidone and olanzapine in elderly psychotic patients. Medical records of 151 hospitalized geropsychiatric patients (risperidone patients n = 114 and olanzapine patients n = 37) were analyzed for demographic data, target symptoms, doses, effects, side effects, comorbid medical conditions and concurrent medications. The mean age of the patients was 71 years. The male: female ratio was essentially the same for both groups. The mean daily dose was 3 mg for risperidone and 10 mg for olanzapine. 78% of the risperidone group and 75% of the olanzapine group appear to have responded to treatment. The discontinuation rates of medication was the same in both groups (22%). Adverse events were reported in 16–17% in both groups. It appears from this study that both risperidone and olanzapine are relatively safe and effective in geropsychiatric patients with comorbid medical illnesses. Controlled studies and head-to-head comparison studies are recommended.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 1, 2004

References

  • The treatment of psychosis in late life
    Zagas, EM; Grossberg, GT
  • Neuroleptic treatment of agitation and psychosis in dementia
    Devanand, DP; Levy, SR
  • Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients
    Jeste, DV; Caligiuri, MP; Paulsen, JS
  • Prospective study of tardive dyskinesia in the elderly
    Saltz, BL; Kane, JM; Woernes, MG
  • Clinical assessments of extrapyramidal signs in nursing home patients given antipsychotic medication
    Avorn, J; Monane, M; Everitt, DE
  • Risperidone in the treatment of schizophrenia
    Marder, SR; Meibach, RC
  • A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients
    Chouinard, G; Jones, B; Remington, C
  • First clinical experience with olanzapine (LY 17 0053): Results of an open label safety and dose ranging study in patients with schizophrenia
    Baldwin, DS; Montgomery, SA
  • Efficacy of olanzapine: An overview of pivotal clinical trials
    Beasley, CM
  • Extrapyramidal symptoms in patients treated with risperidone
    Simpson, GM; Lindenmayer, JP
  • Efficacy of risperidone treatment for psychosis associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series
    Madhusoodanan, S; Brenner, R; Araujo, L; Abaza, A.
  • Risperidone in elderly schizophrenic patients
    Berman, I; Merson, A; Rachov-Pavlov, J
  • Newer antipsychotics and antidepressants for elderly people
    Lacro, JP; Eastham, JH; Jeste, DB; Lohr, JB
  • Outcome of risperidone therapy in elderly patients with chronic psychosis
    Sajotovic, M; Ramirez, L; Vernon, L
  • Risperidone in the elderly: A pharmacoepidemiologic study
    Zarate, CA; Baldessarini, RJ; Siegel, AJ
  • ECDEU Assessment Manual for Psychopharmacology
    Guy, W
  • A clinical update on olanzapine treatment in schizophrenic and in elderly Alzheimer's Disease patients
    Satterlee, WG; Reams, SG; Burns, PR